Trial Profile

A phase I first-in-human, single ascending clinical study assessing OSM 0205

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 23 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs OSM-0205 (Primary)
Indications Chemotherapy-induced damage; Peripheral neuropathies
Focus Adverse reactions; First in man
Sponsors Osmol Therapeutics

Most Recent Events

16 Jun 2025 According to Osmol Therapeutics media release, Company is completing a financing to initiate a Phase 1 study to advance OSM-0205.
18 Sep 2023 According to Osmol Therapeutics media release, that the U.S. Food and Drug Administration (FDA) notified the company that the first-in-human clinical trial of OSM-0205 in healthy subjects for the prevention of CIPN may proceed.
01 Aug 2023 According to Osmol Therapeutics media release, the compay has filed the Investigational New Drug application (IND) with the FDA for OSM-0205.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com